# Safety and Pharmacology of Stanate

> **NCT00115544** · PHASE2 · COMPLETED · sponsor: **InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company** · enrollment: 55 (actual)

## Conditions studied

- Hyperbilirubinemia

## Interventions

- **DRUG:** Stanate

## Key facts

- **NCT ID:** NCT00115544
- **Lead sponsor:** InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115544, "Safety and Pharmacology of Stanate". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00115544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*